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Background: Achromobacter xylosoxidans is increasingly cultured in sputum from cystic fibrosis (CF) patients; nevertheless, there are few
published data on the clinical impact of this infection or chronic colonisation.
Methods: Relying on DNA fingerprinting techniques we studied the prevalence of A. xylosoxidans in our CF population. In a retrospective
case control study the clinical status of patients with at least 3 sputum cultures positive for A. xylosoxidans over at least 9 months, at the
moment of the first positive culture and during the period of colonisation were compared to age (±1 year), gender and to Pseudomonas
aeruginosa colonisation controlled CF patients who had never A. xylosoxidans positive sputum cultures.
Results: The prevalence of patients with at least one positive A. xylosoxidans culture was 17.9%. 5.3% of the patients fulfilled the criteria of
our definition of colonisation.
Colonised patients had a median age of 20 years (range 11–27 years) and a mean colonisation period of 1.5 (±0.9) years.
At the moment of the first positive culture we found significantly lower Bhalla scores on HRCT scans of the lungs (11±3 versus 16±3,
p<0.002), lower Brasfield chest X-ray scores (14±3 versus 18±3, p<0.019), lower FVC values (70%±22 versus 94%±12, p<0.017) and
lower FEV1 values (55%±32 versus 78%±23, p=0.123), although the latter did not reach significance. There was no significant difference
in body mass index (BMI) (18.7±3 kg/m2 versus 19.6±3 kg/m2, p=0.8).
Over the study period A. xylosoxidans-colonised patients did have more need for intravenous antibiotic treatment courses (19 versus 5,
p<0.001); nevertheless, there was no significant difference in lung function decline over the study period (FVC: −6.25±12.34% versus
−5.62±8.30%, p 0.77, FEV1: −5.62±8.30% versus −1.87±11.58%, p<0.47).
Conclusions: The prevalence of A. xylosoxidans infection or colonisation is probably underestimated. Colonised patients are mostly older,
with more pronounced lung damage and lower lung function values. Although there was more need for intravenous antibiotic treatment
courses, no faster decline in lung function was observed in A. xylosoxidans positive patients.
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Although Pseudomonas aeruginosa is the main Gram-
negative pathogen found in the sputum of cystic fibrosis
(CF) patients, recently other Gram-negative bacilli emerge.
Among these emerging pathogens has been Achromobacter
xylosoxidans. The clinical significance of this micro-⁎ Corresponding author. Tel.: +32 9 2403586; fax: +32 9 2403861.
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doi:10.1016/j.jcf.2006.05.011organism is unclear and there is limited evidence to direct
treatment.
A. xylosoxidans is increasingly cultured in CF sputum;
nevertheless, there are few published data on the clinical
impact of this infection or chronic colonisation.
In a group of 557 CF patients, Tan et al. [1] reported a
prevalence of 2.3%, considering patients with at least three
positive cultures over a period of 6 months. In a prospective
multi-centre German study Steinkamp et al. [2] reported a
prevalence of 1.1% among 1419 CF patients. In the Belgian
CF Register 2002 [3], gathering 826 patients, a prevalence ofed by Elsevier B.V. All rights reserved.
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positive culture over the year 2002. The U.S. Cystic Fibrosis
Foundation's National Patient Registry, however, reported
over the last 10 years an increase in prevalence of patients
harbouring A. xylosoxidans: 0.5%, 1.9%, 2.7%, 3.8% and
5.2% in 1995, 1996, 1997, 1999 and 2002, respectively [4].
In order to study the relative risk of cross infection of P.
aeruginosa in our CF population DNA fingerprinting
techniques were carried out on multiple Pseudomonas and/
or Gram-negative non-fermenting bacilli.
Relying on these DNA techniques we studied the
prevalence of A. xylosoxidans in our CF population. We
evaluated the clinical history of CF patients with at least 3
positive sputum cultures for A. xylosoxidans over at least
9 months. In a retrospective case control study we evaluated
the clinical status of the patients at the moment of the first
positive culture and during the period of colonisation.
2. Materials and methods
A. xylosoxidans is a motile Gram-negative, oxidase-
positive rod. The morphology of A. xylosoxidans colonies is
not that different from that of P. aeruginosa colonies.
In our CF centre, taking care of 140 CF patients, P.
aeruginosa strains and strains of morphologically different
looking Gram-negative, non-fermenting bacilli were sent to
the DNA laboratory for further identification using DNA
fingerprinting techniques.
2.1. Isolation and identification
Lactose negative colonies on McConkey agar were
isolated on Mueller Hinton Agar containing 5% sheep
blood, and subsequently tested for oxidase activity. Oxidase
positive isolates were further identified using tDNA-PCR in
combination with fluorescent capillary electrophoresis [5].
This approach enables us to distinguish between Gram-
negative non-fermenters like P. aeruginosa, Burkholderia
species and Achromobacter species (unpublished data), by
comparing the tDNA-PCR fingerprints of unknowns with
those of reference strains in a library (available at http://
usersallserv.ugent.be/~mvaneech/LBR.html). Identification
of isolates as A. xylosoxidans was confirmed by using
API20 NE (bioMérieux, Marcy l'Etoile, France).
2.2. Patients
A retrospective case control study design was used. In our
CF centre each patient is seen on a three monthly basis, when
a clinical history is taken, a sputum culture and a lung
function measurement are done. In young children or none
sputum producers, a pharyngeal swab alternating with a
nasopharyngeal aspirate is taken. Patients with at least 3
positive cultures for A. xylosoxidans over at least 9 months
were compared to subjects who had never grown A.
xylosoxidans, matched for age (±1 year), gender and P.aeruginosa colonisation. Our CF group of 140 patients did
not allow to match each colonized patient with 2 control
patients, unless we enlarged the age limits to ±2 years which
would have weakened our findings because of the large age
range (4 years). Comparison was done for chest X-rays and
high-resolution CT scans, relying on the Brasfield [6] and
Bhalla [7] scores, respectively. Lung function measurements,
forced vital capacity (FVC) and forced expiratory volume in
one second (FEV1) and body mass index (BMI, kg/m
2) were
compared. Over the study period the need for intravenous
antibiotic courses and the decline in lung function were
evaluated.
Data were compared for the period from the first positive
culture for A. xylosoxidans until 31 December 2004, giving a
mean colonisation period of 1.5 (±0.9) years.
Respiratory function tests were performed on a Master-
lab® (Jaeger®).
Respiratory infections in P. aeruginosa colonised patients
are treated for 2–3 weeks with intravenous antibiotics: an
aminoglycoside and a betalactam penicillin. When there was
coexistent A. xylosoxidans infection antibiotics were chosen,
where possible, according to their in vitro activity against
both micro-organisms. Elective three monthly intravenous
antibiotic treatment policy for chronic P. aeruginosa
infection is not practised in our CF clinic. Symptomatic
patients with positive sputum cultures only for A. xylosox-
idans were treated, relying to severity, with two intravenous
antibiotics chosen according to in vitro sensitivity or with an
oral antibiotic (cotrimoxazol or tetracycline) for 2–3 weeks.
Statistical analysis was done using the chi-square test and
the unpaired Student's t-test for normally distributed data.
3. Results
17.9% of our patient population did have at least one
positive culture for A. xylosoxidans.
According to our criteria, the prevalence of A. xylosox-
idans colonisation in our CF-centre was 5.3%. All patients
remained colonised with A. xylosoxidans throughout the
study period.
Eight patients out of 140 at our CF centre were found to
be colonised by A. xylosoxidans. They had a median age of
20 years (range 11–27 years) and a mean colonisation period
of 1.5 (±0.9) years. They were compared to 8 control CF
patients, who have never grown A. xylosoxidans, matched
for age (±1 year), gender and P. aeruginosa colonisation.
Seven patients were co-colonised with P. Aeruginosa,
four by Staphylococcus aureus and Stenotrophomonas
maltophilia was cultured intermittently in 2 patients.
At the moment of the first positive culture we found
significantly lower Bhalla-scores on HRCT scans of the
lungs (11±3 versus 16±3, p<0.002), lower Brasfield chest
X-ray scores (14±3 versus 18±3, p<0.019), lower FVC
values (70±22% versus 94±12%, p<0.017) and lower
FEV1 values (55±32% versus 78±23%, p=0.123), although
the latter did not reach significance. There was no significant
Table 1
Comparison of morphologic and functional parameters at the moment of the
first isolation of A. xylosoxidans (mean±standard deviation)
A. xylosoxidans + A. xylosoxidans − p
BHALLA scores 11±3 16±3 <0.002
Brasfield scores 14±3 18±3 <0.019
FVC (% predicted) 70±22 94±12 <0.017
FEV1 (% predicted) 55±32 78±23 =0.139
BMI (kg/m2) 18.7±3 19.6±3 =0.8
Table 2
The number of IV AB treatment courses and decline in lung function
parameters (mean±standard deviation) over the study period (1.5±
0.9 years)
A. xylosoxidans + A. xylosoxidans − P
IVAB treatment courses 19 5 <.001
Lung function decline
FVC (% predicted) 6.25±12.34 4.5±11.9 =0.77
FEV1 (% predicted) 5.62±8.30 1.87±11.58 =0.47
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p=0.8) (Table 1).
Over the study period, A. xylosoxidans-colonised patients
needed more intravenous antibiotic treatment courses (19
versus 5, p<0.001); nevertheless, there was no significant
difference in lung function decline over the study period
(FVC:−6.25±12.34% versus −5.62±8.30%, p 0.77, FEV1:
−5.62±8.30% versus −1.87±11.58%, p<0.47) (Table 2).
4. Discussion
17.9% of our patient population did have at least one
positive culture for A. xylosoxidans. The prevalence in our
centre was significantly higher than that reported in the
literature [1–4]. However, the prevalence measured in our
population is cumulative and not annual; moreover, because
of an ongoing National Pseudomonas study we relied on
DNA fingerprinting techniques for species identification.
Indeed, some of the isolates, identified genotypically as A.
xylosoxidans, were initially considered as atypical P.
aeruginosa in our routine laboratory, using standard
phenotypic identification. It is well known that, due to the
diversity of colony morphology and biochemical reactivity,
misidentification of Gram-negative non-fermenters cultured
from CF sputum may occur. In one study, misidentification
of 11% of A. xylosoxidans strains was reported [8].
The morphology of Achromobacter colonies is not that
different from the appearance of P. aeruginosa colonies. In
the routine laboratory where specific mediums or DNA
techniques are not available, the true prevalence is probably
underestimated.
The prevalence of A. xylosoxidans colonisation in our CF-
centre was 5.3%.
This is comparable with the findings of Burns et al. [9]
who found as part of the pre-enrolment visits for a study on
the use of the aerosolised tobramycine, over a period of
6 months, a positive culture for A. xylosoxidans on three
different occasions in 7% of the 427 screened patients.
As no consensus definition of colonisation is available,
we are aware that our definition of colonisation is debatable.
At the moment of the first positive culture we found
significantly lower Bhalla scores on HRCT scans of the
lungs, lower Brasfield chest X-ray scores, lower FVC values
and lower FEV1 values, although the latter did not reach
significance. There was no significant difference in BMI.
These findings suggest that particularly patients with morelung damage are prone to infection or colonisation with A.
xylosoxidans. This could explain the older age at which a
first infection is found.
Tan et al. [1] studied 13 patients colonized with A.
xylosoxidans, with a median age of 17.2 years (range 6.5–
32.8). They were compared to 26 control CF-patients
matched for gender, age (±2 years), body weight (±10%),
FEV1 (±10%) and bacterial colonisation. Over a period of
4 years they did not find either a significant difference in
decrease of lung function parameters, neither significant
differences in the use of antibiotics, inhaled antibiotics or
oral or inhaled corticosteroids.
As in their study patients were matched for FEV1, Tan et
al. [1] did not look for lung function differences;
unfortunately, they neither evaluated HRCT-scan scores,
although discrepancy between lung function measurements
and morphologic damage, evaluated by HRCT scan scores
has been reported [10]. Because they had the opportunity to
study a large group of patients, their study would probably
have been more informative if they had included all age-
matched controls irrespective of their FEV1.
We chose in our case control study not to stratify for lung
function.
This study has the weaknesses of all case control studies.
If one matches the control group for lung function, no
conclusions can be made for this parameter as a possible
determinant for A. xylosoxidans colonisation.
Ideally each colonised patient should be compared with as
many controls, matched for age, gender and P. aeruginosa
colonisation as possible, regardless of their lung function.
This would strengthen the findings concerning the possible
role of lung destruction as a permissive factor for
colonisation and the decline in lung function after
colonisation.
A prospective study would of course be more informa-
tive; however, it is difficult to predict who will remain
culture positive and negative over a certain period, and
therefore, large numbers of patients would be required.
Over the study period, A. xylosoxidans-colonised patients
needed more intravenous antibiotic treatment courses. This
finding is not confirmed by the study of Tan et al. [1]. Since
in their CF centre patients with chronic P. aeruginosa
infection received elective three monthly intravenous
antibiotic treatment courses, differences between both
groups possibly have been attenuated. Whether the higher
need for IV antibiotics, as observed in our study, depends on
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pronounced lung damage remains an unanswered question.
Although there seems to be a tendency, there was no
significant difference in lung function decline over the study
period. Probably such differences may become evident after
a longer follow-up period in a larger group of patients.
Until now, a low transmissibility of A. xylosoxidans was
reported. However, recently we reported [11] that out of 13
patients colonised with A. xylosoxidans, staying in a CF-
revalidation centre, 9 patients shared one genotype, three
shared another genotype and one patient had both genotypes,
suggestive for patient-to-patient spread. Accordingly Kanel-
lopoulou et al. [12] reported 9 colonised patients, 5 of them
sharing the same genotype.
Considering the results of Tan et al. [1], who could not
detect a need for more intravenous antibiotic treatment
courses in A. xylosoxidans-colonised patients and our finding
that colonised patients have more damaged lungs, it is
tempting to hypothesize that A. xylosoxidans is a coloniser of
more damaged lungs rather than a destructive infectious
organism; however, it is obvious that more, especially
prospective, studies on the clinical relevance of A.
xylosoxidans infection or colonisation are warranted.
5. Conclusions
Relying on routine laboratory analysis, the prevalence of
A. xylosoxidans infection or colonisation is probably under-
estimated. Mostly older patients, with more pronounced lung
damage and lower lung function values have positive
cultures. Data on the post-acquisition morbidity showed a
higher need for intravenous antibiotic treatment courses. No
significantly faster decline in lung function was observed in
A. xylosoxidans positive patients; however, observations
were done retrospectively in a small number of patients over
a short period; therefore, one should be cautious interpreting
these results. In view of the possibility of patient to patient
spread further longitudinal studies are warranted to elucidate
the clinical impact of A. xylosoxidans infection in CF
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